Reduced muscle mass and bone size in pediatric patients with inflammatory bowel disease

Inflamm Bowel Dis. 2010 Feb;16(2):216-25. doi: 10.1002/ibd.21021.

Abstract

Background: Decreased bone mineral density has been reported in children with inflammatory bowel disease (IBD). We used peripheral quantitative computed tomography (pQCT) to assess bone mineralization, geometry, and muscle cross-sectional area (CSA) in pediatric IBD.

Methods: In a cross-sectional study, pQCT of the forearm was applied in 143 IBD patients (mean age 13.9 +/- 3.5 years); 29% were newly diagnosed, 98 had Crohn's disease, and 45 had ulcerative colitis. Auxological data, cumulative glucocorticoid dose, disease activity indices, laboratory markers for inflammation, and bone metabolism were related to the results of pQCT.

Results: Patients were compromised in height (-0.82 +/- 1.1 SD), weight (-0.77 +/- 1.0 SD), muscle mass (-1.12 +/- 1.0 SD), and total bone cross-sectional area (-0.79 +/- 1.0 SD) compared to age- and sex-matched healthy controls (z-scores). In newly diagnosed patients, the ratio of bone mineral mass per muscle CSA was higher than in those with longer disease duration (1.00 versus 0.30, P = 0.007). Serum albumin level and disease activity correlated with muscle mass, accounting for 41.0% of variability in muscle mass (P < 0.01). The trabecular bone mineral density z-score was on average at the lower normal level (-0.40 +/- 1.3 SD, P < 0.05).

Conclusions: Reduced bone geometry was explained only in part by reduced height. Bone disease in children with IBD seems to be secondary to muscle wasting, which is already present at diagnosis. With longer disease duration, bone adapts to the lower muscle CSA. Serum albumin concentration is a good marker for muscle wasting and abnormal bone development.

MeSH terms

  • Adolescent
  • Body Height
  • Bone Density
  • Bone and Bones / pathology*
  • Child
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / pathology
  • Cross-Sectional Studies
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / pathology*
  • Male
  • Muscles / pathology*
  • Organ Size
  • Severity of Illness Index
  • Time Factors
  • Tomography Scanners, X-Ray Computed
  • Young Adult

Substances

  • Immunosuppressive Agents